NASDAQ: ATXIAvenue Therapeutics Inc Stock
$4.15-0.25 (-5.68%)
Updated May 9, 2024
ATXI Price
$4.15
Fair Value Price
$12.63
Market Cap
$2.45M
52 Week Low
$4.04
52 Week High
$93.75
P/E
-0.06x
P/B
1.55x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$10.38M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.76
Operating Cash Flow
-$9M
Beta
0.58
Next Earnings
Jun 24, 2024
Ex-Dividend
N/A
Next Dividend
N/A
ATXI Overview
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.
Zen Score
–
Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ATXI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ATXI ($4.15) is undervalued by 67.13% relative to our estimate of its Fair Value price of $12.63 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ATXI ($4.15) is significantly undervalued by 67.13% relative to our estimate of its Fair Value price of $12.63 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
ATXI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ATXI due diligence checks available for Premium users.
Be the first to know about important ATXI news, forecast changes, insider trades & much more!
ATXI News
Valuation
ATXI fair value
Fair Value of ATXI stock based on Discounted Cash Flow (DCF)
Price
$4.15
Fair Value
$12.63
Undervalued by
67.13%
ATXI ($4.15) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ATXI ($4.15) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ATXI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ATXI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.06x
Industry
5.22x
Market
29.92x
ATXI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.55x
Industry
5.97x
ATXI is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ATXI's financial health
Profit margin
Revenue
$0.0
Net Income
$640.0k
Profit Margin
0%
ATXI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$1.9M
Liabilities
$1.2M
Debt to equity
0.76
ATXI's short-term assets ($1.85M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ATXI's short-term assets ($1.85M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ATXI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ATXI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.3M
Investing
$0.0
Financing
$3.9M
ATXI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ATXI vs Biotech Stocks
Avenue Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.